ANTX
AN2 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.89
−1.01%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-47.8%
Return on equity
-44.4%
Return on assets
-51.1%
Return on invested capital
0.00x
Asset turnover
-$30.7M
Cash from operations
$2.08
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026